The Indications for Use statement is a specific statement of disease, condition, or anatomical site for which a device is intended, including the patient population. It is a formal part of a 510(k), De Novo or PMA, usually submitted on FDA Form 3881, and appears in the clearance or approval decision. Indications that differ from the predicate's may still allow substantial equivalence if the intended use is the same, but broader or new indications often raise new questions of safety and effectiveness.

Why it matters

Indications for Use is a specific, regulatorily significant subset of intended use, captured in 510(k) and PMA decision summaries.

Common pitfalls

•Confusing "Indications for Use" with "intended use" can lead to mislabeling and regulatory non-compliance.
•Failing to precisely define the patient population or conditions can result in a device being used off-label, creating safety risks.
•Inconsistent Indications for Use across different official documents, such as regulatory submissions and marketing materials, can trigger regulatory scrutiny.
•Not clearly delineating the specific disease or condition the device addresses can lead to ambiguity in its application and efficacy claims.
•Omitting contraindications or warnings within the labeling related to the Indications for Use can result in adverse events and regulatory actions.

Sources

European Commission - Medical Devices · European Commission
IMDRF Documents · IMDRF
RAPS Regulatory Focus · RAPS

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.